RITUXAN + CVP—PROVEN TO EXTEND PROGRESSION-FREE SURVIVAL IN PREVIOUSLY UNTREATED FOLLICULAR NHL

*Patients in the R-CVP arm received RITUXAN 375 mg/m2 on Day 1 of each cycle. All patients received cyclophosphamide 750 mg/m2 on Day 1 of the treatment cycle, vincristine 1.4 mg/m2 (max 2 mg) on Day 1 of the treatment cycle, and prednisone 40 mg/m2 on Days 1-5 of the treatment cycle. 8

RITUXAN + CVP IMPROVED PFS IN FIRST-LINE FOLLICULAR NHL 1

SELECT IMPORTANT SAFETY INFORMATION

RITUXAN IN COMBINATION WITH CVP FOR PREVIOUSLY UNTREATED FOLLICULAR NHL

  • Patients in the R-CVP arm had higher incidences of infusional toxicity and neutropenia compared with those in the CVP arm. The following adverse reactions occurred more frequently (≥5%) in patients receiving R-CVP compared with CVP alone: rash (17% vs. 5%), cough (15% vs. 6%), flushing (14% vs. 3%), rigors (10% vs. 2%), pruritus (10% vs. 1%), neutropenia (8% vs. 3%), and chest tightness (7% vs. 1%)

NHL=non-Hodgkin's lymphoma; CVP=cyclophosphamide, vincristine, and prednisolone; R=RITUXAN; PFS=progression-free survival.

NEXT: Previously Untreated DLBCL >